Pharmacology of Systemic Antifungal Agents (Q57533011)

1

object named as

Elizabeth S. Dodds Ashley

0 references

author name string

James S. Lewis

3

0 references

Craig Martin

4

0 references

David Andes

Clinical Infectious Diseases

5

0 references

language of work or name

English

0 references

publication date

1 August 2006

0 references

published in

0 references

volume

43

0 references

issue

Supplement_1

0 references

page(s)

S28-S39

0 references

cites work

Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions

1 reference

In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans

21 January 2018

1 reference

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

21 January 2018

1 reference

Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates

21 January 2018

1 reference

Effects of voriconazole on Cryptococcus neoformans

21 January 2018

1 reference

Successful use of voriconazole for treatment of Coccidioides meningitis

21 January 2018

1 reference

Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining

21 January 2018

1 reference

In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi

21 January 2018

1 reference

In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.

21 January 2018

1 reference

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

21 January 2018

1 reference

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

21 January 2018

1 reference

Antifungal activity of a new triazole, D0870, compared with four other antifungal agents tested against clinical isolates of Candida and Torulopsis glabrata

21 January 2018

1 reference

Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain

21 January 2018

1 reference

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

21 January 2018

1 reference

In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds

21 January 2018

1 reference

Detection of amphotericin B-resistant Candida isolates in a broth-based system

21 January 2018

1 reference

Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model

21 January 2018

1 reference

Use of the echinocandins (caspofungin) in the treatment of disseminated coccidioidomycosis in a renal transplant recipient

21 January 2018

1 reference

Amphotericin B nephrotoxicity

21 January 2018

1 reference

Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.

21 January 2018

1 reference

Mechanisms of action of 5-fluorocytosine

21 January 2018

1 reference

Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America

21 January 2018

1 reference

Mode of Action of 5-Fluorocytosine and Mechanisms of Resistance

21 January 2018

1 reference

Effect of food on the pharmacokinetics of multiple‐dose oral voriconazole

21 January 2018

1 reference

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

21 January 2018

1 reference

Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients

21 January 2018

1 reference

Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling

21 January 2018

1 reference

Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits

21 January 2018

1 reference

Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans

21 January 2018

1 reference

Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model

21 January 2018

1 reference

Ocular uptake of fluconazole following oral administration

21 January 2018

1 reference

Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans

21 January 2018

1 reference

Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis

21 January 2018

1 reference

Comparison of fluconazole pharmacokinetics in serum, aqueous humor, vitreous humor, and cerebrospinal fluid following a single dose and at steady state.

21 January 2018

1 reference

Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal

21 January 2018

1 reference

Newer systemic antifungal agents : pharmacokinetics, safety and efficacy

21 January 2018

1 reference

Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis

21 January 2018

1 reference

Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers

21 January 2018

1 reference

The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects.

21 January 2018

1 reference

A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution.

21 January 2018

1 reference

Amphotericin B Pharmacokinetics in Humans

21 January 2018

1 reference

The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy

21 January 2018

1 reference

Pharmacokinetics/pharmacodynamics of echinocandins

21 January 2018

1 reference

21 January 2018

1 reference

Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate

21 January 2018

1 reference

Influence of albumin on itraconazole and ketoconazole antifungal activity: results of a dynamic in vitro study

21 January 2018

1 reference

Influence of human serum on antifungal pharmacodynamics with Candida albicans

21 January 2018

1 reference

Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro

21 January 2018

1 reference

Disposition of posaconazole following single-dose oral administration in healthy subjects

21 January 2018

1 reference

Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction

21 January 2018

1 reference

Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease

21 January 2018

1 reference

Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study

21 January 2018

1 reference

Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes

21 January 2018

1 reference

Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation

21 January 2018

1 reference

Potential for interactions between caspofungin and nelfinavir or rifampin

21 January 2018

1 reference

Co-administration of caspofungin and cyclosporine to a kidney transplant patient with pulmonary Aspergillus infection

21 January 2018

1 reference

Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A.

21 January 2018

1 reference

Interaction of common azole antifungals with P glycoprotein

21 January 2018

1 reference

Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model

21 January 2018

1 reference

In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model

21 January 2018

1 reference

Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis

21 January 2018

1 reference

Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.

21 January 2018

1 reference

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

21 January 2018

1 reference

Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy

21 January 2018

1 reference

The safety of voriconazole

21 January 2018

1 reference

In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis

21 January 2018

1 reference

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

21 January 2018

1 reference

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens

21 January 2018

1 reference

Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.

21 January 2018

1 reference

Amphotericin B: time for a new "gold standard".

21 January 2018

1 reference

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

Systemic Antifungal Therapy: New Options, New Challenges

21 January 2018

1 reference

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

21 January 2018

1 reference

Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia

21 January 2018

1 reference

Triad of Acute Infusion‐Related Reactions Associated with Liposomal Amphotericin B: Analysis of Clinical and Epidemiological Characteristics

21 January 2018

1 reference

Alopecia associated with fluconazole therapy

21 January 2018

1 reference

High-dose itraconazole in the treatment of severe mycoses

21 January 2018

1 reference

Congestive heart failure associated with itraconazole

21 January 2018

1 reference

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

Voriconazole-induced retinoid-like photosensitivity in children

21 January 2018

1 reference

Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole.

21 January 2018

1 reference